FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during the outbreak of the coronavirus in California.REUTERS: Gilead Sciences Inc faces a new dilemma in deciding how much it should profit from the only treatment so far proven to help patients infected with COVID-19.
FILE PHOTO: An ampule of Ebola drug Remdesivir is pictured at the University Hospital Eppendorf in Hamburg, Germany, on Apr 8, 2020, as the spread of coronavirus continues. Ulrich Perrey/Pool via REUTERSWall Street analysts say remdesivir could generate US$750 million or more in worldwide sales next year, and US$1.1 billion in 2022, assuming the pandemic continues.
Gilead also aims to increase worldwide manufacturing to supply over a million coronavirus patients by year-end, rising to several million in 2021, if required. The company has not disclosed its pricing plans. Consumer advocacy group Public Citizen on Monday said remdesivir should be priced at US$1 per day of treatment, since"that is more than the cost of manufacturing at scale with a reasonable profit to Gilead."
profit